CCI Approves Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India (CCI) gave approval to Mankind Pharma's acquisition of Bharat Serums and Vaccines for Rs 13,630 crore. Mankind Pharma, a publicly traded company, is involved in creating, producing, and selling a wide variety of pharmaceutical finished dosage forms.

"Commission approves acquisition of Bharat Serums and Vaccines Limited by Mankid Pharma Ltd," the regulator said in a post on X.

Mankind, along with its affiliated companies, is engaged in the production and distribution of APIs, pharmaceutical intermediates, and packaging materials for pharmaceutical items.

Bharat Serums and Vaccines Ltd (BSV) is involved in the research, development, licensing, manufacturing, importing, exporting, marketing, and distribution of pharmaceutical formulations/ FDFs, APIs, food, and health supplements. BSV is a top company in the biopharmaceutical industry with a focus on women's healthcare, assisted reproductive treatment, critical care, and emergency medicine.

Mankind Pharma revealed in July of this year its decision to fully purchase Bharat Serums and Vaccines from private equity firm Advent International for approximately Rs 13,630 crore. The company has finalized a deal to purchase the entire ownership of BSV for approximately Rs 13,630 crore.

This strategic decision represents a major advancement for the pharmaceutical company, establishing its presence as a top player in the Indian market for women's health and fertility drugs, in addition to providing access to other difficult-to-enter products in critical care utilizing advanced R&D technology platforms.